JP2004536810A - シクロデキストリンを用いたｓ−オメプラゾール（ｅｓオメプラゾール）の包接複合体 - Google Patents

シクロデキストリンを用いたｓ−オメプラゾール（ｅｓオメプラゾール）の包接複合体 Download PDF

Info

Publication number
JP2004536810A
JP2004536810A JP2003501462A JP2003501462A JP2004536810A JP 2004536810 A JP2004536810 A JP 2004536810A JP 2003501462 A JP2003501462 A JP 2003501462A JP 2003501462 A JP2003501462 A JP 2003501462A JP 2004536810 A JP2004536810 A JP 2004536810A
Authority
JP
Japan
Prior art keywords
omeprazole
cyclodextrin
inclusion complex
complex
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003501462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536810A5 (https=
Inventor
ハミエド、ユスフ・クワジャ
ラオ、ダーマライ・ラマチャンドラ
Original Assignee
シプラ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シプラ・リミテッド filed Critical シプラ・リミテッド
Publication of JP2004536810A publication Critical patent/JP2004536810A/ja
Publication of JP2004536810A5 publication Critical patent/JP2004536810A5/ja
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2003501462A 2001-06-06 2002-06-06 シクロデキストリンを用いたｓ−オメプラゾール（ｅｓオメプラゾール）の包接複合体 Pending JP2004536810A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0113792A GB2376231A (en) 2001-06-06 2001-06-06 Benzimidazole-cyclodextrin inclusion complex
PCT/GB2002/002542 WO2002098423A1 (en) 2001-06-06 2002-06-06 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins

Publications (2)

Publication Number Publication Date
JP2004536810A true JP2004536810A (ja) 2004-12-09
JP2004536810A5 JP2004536810A5 (https=) 2005-12-22

Family

ID=9916040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003501462A Pending JP2004536810A (ja) 2001-06-06 2002-06-06 シクロデキストリンを用いたｓ−オメプラゾール（ｅｓオメプラゾール）の包接複合体

Country Status (17)

Country Link
US (1) US20040147481A1 (https=)
EP (1) EP1401442B1 (https=)
JP (1) JP2004536810A (https=)
AT (1) ATE282412T1 (https=)
AU (1) AU2002344386B2 (https=)
CA (1) CA2449769C (https=)
DE (1) DE60201995T2 (https=)
ES (1) ES2232780T3 (https=)
GB (1) GB2376231A (https=)
LT (1) LT5182B (https=)
LV (1) LV13154B (https=)
NZ (1) NZ529956A (https=)
PL (1) PL366940A1 (https=)
PT (1) PT1401442E (https=)
RU (1) RU2313343C2 (https=)
WO (1) WO2002098423A1 (https=)
ZA (1) ZA200309841B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 ｓ-오메프라졸 함유 포접 복합체 및이의 제조방법
ATE428707T1 (de) 2005-12-28 2009-05-15 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
WO2009040825A1 (en) 2007-09-25 2009-04-02 Hetero Drugs Limited A process for preparation of enantiomerically pure esomeprazole
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN104277030B (zh) * 2013-07-03 2016-04-20 湖南理工学院 一种反应萃取分离泮托拉唑对映体的方法
CN103768028A (zh) * 2014-01-15 2014-05-07 山东新时代药业有限公司 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509499A (ja) * 1993-05-28 1995-10-19 アストラゼネカ・アクチエボラーグ 新規な化合物
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
WO2001014367A1 (en) * 1999-08-26 2001-03-01 Applied Analytical Industries, Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
JP2001518083A (ja) * 1997-03-13 2001-10-09 ヘキサル アーゲー アミノ酸／シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化
JP2003507475A (ja) * 1999-08-26 2003-02-25 エイエイアイファーマ・インコーポレイテッド アルコキシ置換ベンズイミダゾール化合物、それを含む医薬製剤物、およびそれを使用する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
TW224049B (https=) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
ES2149750T3 (es) * 1999-01-06 2004-06-01 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos.
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509499A (ja) * 1993-05-28 1995-10-19 アストラゼネカ・アクチエボラーグ 新規な化合物
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
JP2001518083A (ja) * 1997-03-13 2001-10-09 ヘキサル アーゲー アミノ酸／シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化
WO2001014367A1 (en) * 1999-08-26 2001-03-01 Applied Analytical Industries, Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
JP2003507475A (ja) * 1999-08-26 2003-02-25 エイエイアイファーマ・インコーポレイテッド アルコキシ置換ベンズイミダゾール化合物、それを含む医薬製剤物、およびそれを使用する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARIAS M J, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. V3N26, JPN5003019901, March 2000 (2000-03-01), US, pages 253 - 259, ISSN: 0001204000 *
CASTILLO J A, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. V25N12, JPN5003019902, December 1999 (1999-12-01), US, pages 1241 - 1248, ISSN: 0001204001 *

Also Published As

Publication number Publication date
LT2003100A (en) 2004-09-27
CA2449769A1 (en) 2002-12-12
ES2232780T3 (es) 2005-06-01
EP1401442B1 (en) 2004-11-17
ZA200309841B (en) 2005-03-14
RU2313343C2 (ru) 2007-12-27
LV13154B (en) 2004-07-20
CA2449769C (en) 2010-12-14
PL366940A1 (en) 2005-02-07
LT5182B (lt) 2004-12-27
PT1401442E (pt) 2005-02-28
GB2376231A (en) 2002-12-11
AU2002344386B2 (en) 2006-11-30
ATE282412T1 (de) 2004-12-15
HK1064602A1 (en) 2005-02-04
US20040147481A1 (en) 2004-07-29
EP1401442A1 (en) 2004-03-31
RU2003137221A (ru) 2005-06-10
GB0113792D0 (en) 2001-07-25
DE60201995T2 (de) 2005-11-24
DE60201995D1 (de) 2004-12-23
NZ529956A (en) 2005-07-29
WO2002098423A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
US6410569B1 (en) Salt form of pantoprazole
SK285151B6 (sk) Neutrálna forma S-enantioméru omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie
HUP0400781A2 (hu) Eljárás (R)- vagy (S)-lansoprazol kristályosítására, az előállított kristályok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2001002389A1 (en) Crystals of benzimidazole compounds
EP1018340B1 (en) Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them
KR100619200B1 (ko) 개선된 화학적 제조 방법 및 제약 제형
JP2004536810A (ja) シクロデキストリンを用いたｓ−オメプラゾール（ｅｓオメプラゾール）の包接複合体
AU2002344386A1 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
JP3283252B2 (ja) ベンズイミダゾール化合物の結晶
JP2014169302A (ja) （ｓ）−オメプラゾールのマグネシウム塩の固形形態とその製造方法
JP5457632B2 (ja) エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法
HK1064602B (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
WO2005070426A1 (en) Freeze-dried (-)-pantoprazole preparation and (-)-pantoprazole injection
JP2001072675A (ja) ベンズイミダゾール化合物の結晶
JP4536905B2 (ja) ベンズイミダゾール化合物の結晶
JP2009518394A (ja) エソメプラゾールの非塩形態の新規の製造方法
JPWO2001002389A1 (ja) ベンズイミダゾール化合物の結晶
CH697390B1 (de) Orale pharmazeutische Formulierung für Pyridylmethylsulfinyl-Benzimidazole und Verfahren zu ihrer Herstellung.
KR20030016232A (ko) 경구 투여 가능한 산 안정성 항궤양 벤즈이미다졸 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090316

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090901